The global Guillain–Barré Syndrome (GBS) market was valued at USD 613.92 million in 2023 and is forecast to grow from USD 644.24 million in 2024 to USD 960.58 million by 2032, exhibiting a CAGR of 5.1% during the forecast period. Market expansion is being driven by rising awareness and diagnosis rates, broader access to standard-of-care...